Featured Story | By Nick Paul Taylor Moderna has landed R&D deals with Vertex and Chiesi worth $100 million upfront. Vertex struck the larger of the two pacts, agreeing to pay Moderna $75 million to collaborate on gene editing cystic fibrosis therapies. read more |
| |
|---|
|
|  | Sterile Filling with Eurofins Eurofins BioPharma Product Testing can help eliminate human error and other associated risks when producing small batches of sterile GMP product for Phase 1 and 2 trials using our state-of-the-art vial filler. Learn More. |
Top Stories By Ben Adams The PCSK9 inhibitor market has to date not made good on its major sales promise, with the likes of Amgen and Sanofi in a price-cutting war for the heart drugs. read more By Arlene Weintraub More than 50 drugs targeting kinases have been approved in the U.S. so far. Many more are queuing up for FDA review. And emerging targets like KRAS, MET and RET are not only inspiring novel kinase inhibitor development, but spurring billions in pharma deals, too. read more Sponsored by: Fierce Biotech The Fierce Innovation Awards: Life Sciences Edition have come to a close and we're pleased to announce the 2020 award winners! read more By Amirah Al Idrus Cytokines have long held great promise as cancer treatments but they can cause side effects that have limited their use. They’re not a very good drug because they haven’t evolved as drugs, but as signaling molecules, says Debanjan Ray, CEO of Synthekine, a biotech with a two-pronged plan to develop cytokine treatments for cancer and autoimmune disease. read more By Amirah Al Idrus When Sean Bohen left AstraZeneca in spring last year, he didn’t know where he was going to end up. At first, he figured he’d end up in another Big Pharma job, but after “looking around broadly” and taking some time off, he’s landed at Olema Oncology, a startup focused on treatments for women’s cancers, as its CEO. read more By Nick Paul Taylor Lava Therapeutics has raised $83 million to advance its portfolio of bispecific gamma delta T-cell engagers. The series C positions Lava to begin assessing the drugs in proof-of-concept clinical trials in solid tumors and hematological malignancies starting next year. read more By Amy Sokolow Taking antibiotics is “like carpet bombing your microbiome," according to Finch Therapeutics CEO Mark Smith, Ph.D., and it can lead to nasty infections like C. difficile. Finch is working on a treatment that repopulates a patient’s gut with healthy microbes to banish C. diff., and it’s just raised $90 million to fuel its efforts. read more By Conor Hale Since launching Grail into the world in 2016, Illumina has watched the cancer blood test developer grow into a multibillion-dollar startup enterprise by amassing multiple nine-digit funding rounds. read more By Ben Adams Clinical trial firm Phesi’s new report is some grim reading for the life science industry: Despite some forward motion over the summer, studies for new drugs are still suffering. read more By Arlene Weintraub Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice. The company raised $73 million in a series A funding earlier this year to advance that program and others into clinical trials. read more |  | LabConnect is now offering global analytical and operational services to meet your COVID-19 testing requirements. We offer viral load testing by RT-qPCR and multiple COVID-19 screening assays. Connect with LabConnect today. We are here to help. |
Resources Sponsored by: Evidation Health Achieving patient centricity depends on evolving how evidence is generated. Sponsored by: Outer Edge Technology Cybercriminals Are Actively Exploiting The Coronavirus Pandemic To Gain Entry To Enterprise Networks. Don’t Let Your Company Become The Next Ransomware Headline -- Make These Changes Now! Sponsored by: 4G Clinical This white paper addresses the complexity of basket and umbrella designs, and how modern technology is critical to run flexible, agile and quality-driven trials. Sponsored by: EVERSANA How independent drug launch and commercialization can lead to higher market capitalization. Sponsored by: AMRI Download our white paper to learn more about the growth trends, complex anatomy and intricacies of developing these armed antibodies, as well as AMRI’s approach to their discovery and development. Sponsored by: LexisNexis Risk Solutions Avoid severe compliance penalties by staying on top of evolving laws. Sponsored by: Quotient Sciences This white paper will discuss four principal CMC challenges for the developers of orphan drugs, and the potential solutions which are emerging. Download now >> Sponsored by: Clarify Health In 2020, QED Therapeutics launched first-in-class infigratinib for cholangiocarcinoma (CCA). Learn how the launch team precisely identified and characterized eligible patients by taking an evidence-based approach to its commercial strategy. Sponsored by: Benchling Life science R&D generates a LOT of data. Learn how to make sense of it and harness its potential with this step-by-step guide. Sponsored by: Thermo Fisher Scientific Don’t oversimplify your solubility challenges. Sponsored by: Clinical Ink Download this free whitepaper to learn how to execute fast, high-quality clinical trials through eSource for studies that boost efficiency for both sponsors and sites. Sponsored by: PRA Health Sciences Drug developers and stakeholders must find ways to collaborate, rather than compete, as the RACE Act prompts the need for more pediatric research. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Thermo Fisher Scientific Download the whitepaper to learn more. Sponsored by: LexisNexis Risk Solutions Traditionally, pharma companies use a combination of prescription data & internal sales reports to look for potential buyers. Such practice provides only a LIMITED VIEW without competitor information. Download the whitepaper by Optum to see how novel data platforms can uncover hidden insights on medication adherence helping life sciences companies maximize product utilization. Sponsored by: Catalent Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better. Sponsored by: Paysign Download the whitepaper for a solution designed to connect manufacturers, pharmacists, and patients. In this special guide, you will learn not just about the law but about the portal platform designed to change the entire process for all. Sponsored by: Cardinal Health 3PL Services Identifying opportunities to simplify channel strategies and business processes for biopharma companies, their customers and patients. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. | 
